Immatics Builds on Genedata Biologics for Cell Therapy Innovation

Immatics performed a comprehensive market assessment, based on their specific requirements, before choosing Genedata Biologics®. While the preference was for a commercial off-the-shelf (COTS) product to provide a maximum of built-in functionalities, facilitate deployment, and ensure future maintenance, a custom development project was also considered. During the deployment project, Genedata worked closely with Immatics to optimally set up the platform and configure Immatics-specific CGT workflows. With extensive domain knowledge and experience from working with both small and large cell and gene therapy companies, Genedata knows how to accelerate, simplify, and optimize specialized CGT processes directly with each customer. Genedata Biologics is now used productively for all proprietary and partnered R&D programs at Immatics, including bispecifics and adoptive cell therapies. As an integrated workflow platform, it enables efficient screening, engineering, production, and testing of TCRs and TCR-based molecules, as well as lentivirus production and cell line development. The system comprehensively tracks properties of each therapeutic candidate, including specificity, efficacy, safety, stability, manufacturability, and developability. It also provides the necessary scalability to support Immatics’ quickly growing R&D organization.